These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35506061)

  • 21. Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.
    Stefani S; Castiglia P; Maida A; Muresu E; Mezzatesta ML; Nicoletti G
    J Chemother; 1990 Oct; 2(5):295-9. PubMed ID: 1965317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SHV Hyperproduction as a Mechanism for Piperacillin-Tazobactam Resistance in Extended-Spectrum Cephalosporin-Susceptible
    Han MS; Park KS; Jeon JH; Lee JK; Lee JH; Choi EH; Lee SH
    Microb Drug Resist; 2020 Apr; 26(4):334-340. PubMed ID: 31651221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
    Chang SC; Hsu LY; Luh KT; Hsieh WC
    J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of the in vitro activity of piperacillin/tazobactam.
    Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
    Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.
    Lister PD; Prevan AM; Sanders CC
    Antimicrob Agents Chemother; 1997 Apr; 41(4):721-7. PubMed ID: 9087477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Investigators of the Piperacillin/Tazobactam Intra-abdominal Infection Study Group.
    Eur J Surg Suppl; 1994; (573):61-6. PubMed ID: 7524798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone resistance-determining regions.
    Hirakata Y; Ohmori K; Mikuriya M; Saika T; Matsuzaki K; Hasegawa M; Hatta M; Yamamoto N; Kunishima H; Yano H; Kitagawa M; Arai K; Kawakami K; Kobayashi I; Jones RN; Kohno S; Yamaguchi K; Kaku M
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4225-30. PubMed ID: 19651910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
    Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S
    J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli.
    Rodríguez-Villodres Á; Gutiérrez Linares A; Gálvez-Benitez L; Pachón J; Lepe JA; Smani Y
    Microbiol Spectr; 2021 Oct; 9(2):e0080121. PubMed ID: 34668721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
    Fass RJ; Prior RB
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.
    Bonfiglio G; Livermore DM
    J Antimicrob Chemother; 1993 Sep; 32(3):431-44. PubMed ID: 8262865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates.
    Cullmann W; Stieglitz M
    Chemotherapy; 1990; 36(5):356-64. PubMed ID: 2170081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
    Schoonover LL; Occhipinti DJ; Rodvold KA; Danziger LH
    Ann Pharmacother; 1995 May; 29(5):501-14. PubMed ID: 7655135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The treatment of severe intra-abdominal infections: the role of piperacillin/tazobactam.
    Nord CE
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S35-8. PubMed ID: 7962987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility of beta-lactamase-producing enterococci to piperacillin with tazobactam.
    Okhuysen PC; Singh KV; Murray BE
    Diagn Microbiol Infect Dis; 1993 Oct; 17(3):219-24. PubMed ID: 8112031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [No Abstract]   [Full Text] [Related]  

  • 40. Piperacillin/tazobactam in the treatment of polymicrobial infections.
    Gorbach SL
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S27-34. PubMed ID: 7962986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.